Can drug combo before surgery boost ovarian cancer outcomes?

NCT ID NCT04644289

Recruiting now Disease control Sponsor: AGO Research GmbH Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether giving the drugs olaparib (Lynparza) alone or combined with durvalumab (Imfinzi) before surgery is feasible and safe for people with advanced ovarian cancer. About 60 participants will receive the drugs for a short time before their planned tumor-removal surgery. The main goal is to see if the treatment can be completed without delays or major side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: olaparib (Lynparza) and durvalumab (Imfinzi)
What this could lead to: If successful, this could show that giving these drugs before surgery is a safe and practical way to shrink tumors, potentially improving surgical outcomes for ovarian cancer.
What could go wrong: This is a small, early-phase trial with only 60 participants, so results may not apply to everyone. The drugs can cause side effects, and there is a risk of treatment delaying surgery or not working as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Carcinoma, Ovarian Epithelial ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPITHELIAL OVARIAN CANCER

Contacts and locations

Locations

Charité Berlin, Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie
RECRUITING

Berlin, State of Berlin, 13353, Germany
KEM Essen | Evang. Kliniken Essen Mitte
RECRUITING

Essen, North Rine-Westphalia, 45136, Germany
Klinikum rechts der Isar, Technische Universität München, Klinik und Poliklinik für Frauenheilkunde
RECRUITING

München, Bavaria, 81675, Germany
Mammazentrum HH am Krankenhaus Jerusalem, Gynäkologisches Operationszentrum Hamburg
RECRUITING

Hamburg, Free and Hanseatic City of Hamburg, 20357, Germany
Universitätsklinikum Carl Gustav Carus Dresden an der technischen Universität Dresden, Gynäkologisches Krebszentrum und Regionales Brustzentrum Dresden am Universitäts-KrebsCentrum
RECRUITING

Dresden, Saxony, 01307, Germany
Universitätsklinikum Mannheim GmbH, Frauenklinik
RECRUITING

Mannheim, Baden-Wurttemberg, 68167, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.